Brief: Aequus Pharmaceuticals Inc - Commercial Relationship With Sandoz Regarding Glaucoma Medication Vistitan Will Remain In Place Until Feb 2022
09/06/2021 13:47
June 9 (Reuters) - Aequus Pharmaceuticals Inc AQS.V :
* AEQUUS PHARMACEUTICALS INC - COMMERCIAL RELATIONSHIP WITH
SANDOZ
REGARDING GLAUCOMA MEDICATION VISTITAN WILL REMAIN IN PLACE
UNTIL FEB 2022
Source text for Eikon: ID:nGNX7SqgmK
Further company coverage: AQS.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aequus Pharmaceuticals
See all newsBrief: Aequus Pharmaceutical Canada Pauses Sales Of Evolve Intensive Eyedrops, Gel In Canada
Brief: Aequus Announces Financing To Support Launch Of Zimed Preservative Free (Bimatoprost 0.03%) And Board Update
Brief: Aequus Announces Health Canada Notice Of Compliance For Zimed® Preservative Free
Brief: Aequus Announces Sandoz Contract Expiry At Year End And Expected Health Canada Approval For Zimed® Pf (Preservative Free)
Brief: Aequus Resumes Trading On TSX Venture Exchange